Katherine R Tuttle

List of Publications by Year
in descending order

203	18,550	25034 57	12946 131
papers	citations	h-index	g-index

213	213	213	17844
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 2032-2045.	4.5	1,600
2	Preserving renal function in adults with hypertension and diabetes: A consensus approach. American Journal of Kidney Diseases, 2000, 36, 646-661.	1.9	1,314
3	Is There a Pathogenetic Role for Uric Acid in Hypertension and Cardiovascular and Renal Disease?. Hypertension, 2003, 41, 1183-1190.	2.7	1,121
4	A causal role for uric acid in fructose-induced metabolic syndrome. American Journal of Physiology - Renal Physiology, 2006, 290, F625-F631.	2.7	889
5	Kidney Disease and Increased Mortality Risk in Type 2 Diabetes. Journal of the American Society of Nephrology: JASN, 2013, 24, 302-308.	6.1	862
6	Stenting and Medical Therapy for Atherosclerotic Renal-Artery Stenosis. New England Journal of Medicine, 2014, 370, 13-22.	27.0	804
7	Diabetic Kidney Disease: A Report From an ADA Consensus Conference. Diabetes Care, 2014, 37, 2864-2883.	8.6	781
8	KDIGO 2020 Clinical Practice Guideline for Diabetes Management in Chronic Kidney Disease. Kidney International, 2020, 98, S1-S115.	5.2	692
9	Clinical Manifestations of Kidney Disease Among US Adults With Diabetes, 1988-2014. JAMA - Journal of the American Medical Association, 2016, 316, 602.	7.4	669
10	Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy. Lancet, The, 2017, 390, 1888-1917.	13.7	662
11	Diabetic Kidney Disease: A Report From an ADA ConsensusÂConference. American Journal of Kidney Diseases, 2014, 64, 510-533.	1.9	439
12	Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes and Endocrinology,the, 2018, 6, 605-617.	11.4	392
13	Hypothesis: fructose-induced hyperuricemia as a causal mechanism for the epidemic of the metabolic syndrome. Nature Clinical Practice Nephrology, 2005, 1, 80-86.	2.0	293
14	The Effect of Ruboxistaurin on Nephropathy in Type 2 Diabetes. Diabetes Care, 2005, 28, 2686-2690.	8.6	283
15	Design of the Nephrotic Syndrome Study Network (NEPTUNE) to evaluate primary glomerular nephropathy by a multidisciplinary approach. Kidney International, 2013, 83, 749-756.	5.2	268
16	Meta-Analysis Comparing Mediterranean to Low-Fat Diets for Modification of Cardiovascular Risk Factors. American Journal of Medicine, 2011, 124, 841-851.e2.	1.5	253
17	Serum Urate Lowering with Allopurinol and Kidney Function in Type 1 Diabetes. New England Journal of Medicine, 2020, 382, 2493-2503.	27.0	228
18	Predictors of ARF after cardiac surgical procedures. American Journal of Kidney Diseases, 2003, 41, 76-83.	1.9	201

#	Article	IF	Citations
19	Effect of Strict Glycemic Control on Renal Hemodynamic Response to Amino Acids and Renal Enlargement in Insulin-Dependent Diabetes Mellitus. New England Journal of Medicine, 1991, 324, 1626-1632.	27.0	195
20	Executive summary of the 2020 KDIGO Diabetes Management in CKD Guideline: evidence-based advances in monitoring and treatment. Kidney International, 2020, 98, 839-848.	5.2	193
21	Linking Metabolism and Immunology: Diabetic Nephropathy Is an Inflammatory Disease. Journal of the American Society of Nephrology: JASN, 2005, 16, 1537-1538.	6.1	184
22	Immunity and inflammation in diabetic kidney disease: translating mechanisms to biomarkers and treatment targets. American Journal of Physiology - Renal Physiology, 2017, 312, F716-F731.	2.7	184
23	JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrology Dialysis Transplantation, 2018, 33, 1950-1959.	0.7	183
24	Reducing major risk factors for chronic kidney disease. Kidney International Supplements, 2017, 7, 71-87.	14.2	155
25	Sex differences in uric acid and risk factors for coronary artery disease. American Journal of Cardiology, 2001, 87, 1411-1414.	1.6	146
26	Clinical Characteristics of and Risk Factors for Chronic Kidney Disease Among Adults and Children. JAMA Network Open, 2019, 2, e1918169.	5.9	130
27	Diabetes and CKD in the United States Population, 2009â€“2014. Clinical Journal of the American Society of Nephrology: CJASN, 2017, 12, 1984-1990.	4.5	117
28	Molecular mechanisms and therapeutic targets for diabetic kidney disease. Kidney International, 2022, 102, 248-260.	5.2	112
29	Diabetes Management in Chronic Kidney Disease: Synopsis of the 2020 KDIGO Clinical Practice Guideline. Annals of Internal Medicine, 2021, 174, 385-394.	3.9	110
30	Comparison of Low-Fat Versus Mediterranean-Style Dietary Intervention After First Myocardial Infarction (from The Heart Institute of Spokane Diet Intervention and Evaluation Trial)â€â€Conflicts of interest: Dr. Bibus has received consulting fees from companies that make fish oil, Coromega Co., Vista, CA, and Enreco, Inc., Newton, WI. He also has equity ownership in Lipid Technologies, LLC, Austin, MN, the company that performed the plasma fatty acid analysis. Dr. Bibus owns patents related to lipid therapy. H. American Journal of Cardiology, 2008, 101, 1523-1530.	1.6	109
31	JAK inhibition in the treatment of diabetic kidney disease. Diabetologia, 2016, 59, 1624-1627.	6.3	107
32	Cardiorenal Protection With the Newer Antidiabetic Agents in Patients With Diabetes and Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2020, 142, e265-e286.	1.6	107
33	SGLT2 Inhibition for the Prevention and Treatment of Diabetic Kidney Disease: A Review. American Journal of Kidney Diseases, 2018, 72, 267-277.	1.9	102
34	Metabolic Effects of Diet and Exercise in Patients with Moderate to Severe CKD: A Randomized Clinical Trial. Journal of the American Society of Nephrology: JASN, 2018, 29, 250-259.	6.1	95
35	Impact of the COVID-19 pandemic on clinical research. Nature Reviews Nephrology, 2020, 16, 562-564.	9.6	94
36	Rationale and design of the Kidney Precision Medicine Project. Kidney International, 2021, 99, 498-510.	5.2	94

#	Article	IF	Citations
37	Longitudinal Relationships among Coronary Artery Calcification, Serum Phosphorus, and Kidney Function. Clinical Journal of the American Society of Nephrology: CJASN, 2009, 4, 1968-1973.	4.5	91
38	Inflammatory Mechanisms as New Biomarkers and Therapeutic Targets for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2018, 25, 181-191.	1.4	91
39	Development of an International Standard Set of Value-Based Outcome Measures for Patients With Chronic Kidney Disease: A Report of the International Consortium for Health Outcomes Measurement (ICHOM) CKD Working Group. American Journal of Kidney Diseases, 2019, 73, 372-384.	1.9	90
40	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. American Journal of Kidney Diseases, 2021, 77, 94-109.	1.9	88
41	Lack of change of lipoprotein (a) concentration with improved glycemic control in subjects with type II diabetes. Metabolism: Clinical and Experimental, 1992, 41, 116-120.	3.4	87
42	Kidney Outcomes in Long-Term Studies of Ruboxistaurin for Diabetic Eye Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2007, 2, 631-636.	4.5	87
43	Incretin drugs in diabetic kidney disease: biological mechanisms and clinical evidence. Nature Reviews Nephrology, 2021, 17, 227-244.	9.6	87
44	A novel potential therapy for diabetic nephropathy and vascular complications: protein kinase C Î² inhibition. American Journal of Kidney Diseases, 2003, 42, 456-465.	1.9	85
45	Sodiumâ€“Glucose Cotransporter 2 Inhibition and Diabetic Kidney Disease. Diabetes, 2019, 68, 248-257.	0.6	80
46	Risks of Subsequent Hospitalization and Death in Patients with Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2012, 7, 409-416.	4.5	78
47	Glycemic Monitoring and Management in Advanced Chronic Kidney Disease. Endocrine Reviews, 2020, 41, 756-774.	20.1	77
48	Advanced Glycation End Products and Nephrotoxicity of High-Protein Diets. Clinical Journal of the American Society of Nephrology: CJASN, 2006, 1, 1293-1299.	4.5	75
49	New Therapies for Diabetic Kidney Disease. New England Journal of Medicine, 2013, 369, 2549-2550.	27.0	75
50	Urinary albumin and insulin as predictors of coronary artery disease: An angiographic study. American Journal of Kidney Diseases, 1999, 34, 918-925.	1.9	71
51	Back to the Future: Glomerular Hyperfiltration and the Diabetic Kidney. Diabetes, 2017, 66, 14-16.	0.6	68
52	CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease. American Journal of Kidney Diseases, 2019, 73, 218-229.	1.9	68
53	Burden of Chronic Kidney Disease by KDIGO Categories of Glomerular Filtration Rate and Albuminuria: A Systematic Review. Advances in Therapy, 2021, 38, 180-200.	2.9	66
54	International consensus definitions of clinical trial outcomes for kidney failure: 2020. Kidney International, 2020, 98, 849-859.	5.2	65

#	Article	IF	Citations
55	Serum amyloid A and inflammation in diabetic kidney disease and podocytes. Laboratory Investigation, 2015, 95, 250-262.	3.7	64
56	Dietary Amino Acids and Blood Pressure: A Cohort Study of Patients With Cardiovascular Disease. American Journal of Kidney Diseases, 2012, 59, 803-809.	1.9	59
57	Therapeutic Considerations for Antihyperglycemic Agents in Diabetic Kidney Disease. Journal of the American Society of Nephrology: JASN, 2017, 28, 2263-2274.	6.1	59
58	Novel Therapies for Diabetic Kidney Disease. Advances in Chronic Kidney Disease, 2014, 21, 121-133.	1.4	55
59	Effects of onceâ€weekly dulaglutide on kidney function in patients with type 2 diabetes in phase <scp>II</scp> and <scp>III</scp> clinical trials. Diabetes, Obesity and Metabolism, 2017, 19, 436-441.	4.4	54
60	Complete Remission in the Nephrotic Syndrome Study Network. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 81-89.	4.5	53
61	SGLT2 Inhibition for CKD and Cardiovascular Disease in Type 2 Diabetes: Report of a Scientific Workshop Sponsored by the National Kidney Foundation. Diabetes, 2021, 70, 1-16.	0.6	53
62	Effect of Ruboxistaurin on Urinary Transforming Growth Factor-Â in Patients With Diabetic Nephropathy and Type 2 Diabetes. Diabetes Care, 2007, 30, 995-996.	8.6	50
63	Relationship of Albuminuria and Renal Artery Stent Outcomes. Hypertension, 2016, 68, 1145-1152.	2.7	50
64	The New KDOQI^{TM} Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and CKD. Blood Purification, 2007, 25, 112-114.	1.8	48
65	Uric Acid, Microalbuminuria and Cardiovascular Events in High-Risk Patients. American Journal of Nephrology, 2005, 25, 36-44.	3.1	45
66	Serum Calcification Propensity and Fetuin-A: Biomarkers of Cardiovascular Disease in Kidney Transplant Recipients. American Journal of Nephrology, 2018, 48, 21-31.	3.1	42
67	Obesity Management in Adults With CKD. American Journal of Kidney Diseases, 2009, 53, 151-165.	1.9	41
68	Renal Artery Stent Outcomes. Journal of the American College of Cardiology, 2015, 66, 2487-2494.	2.8	40
69	Clinical Characteristics and Treatment Patterns of Children and Adults With IgA Nephropathy or IgA Vasculitis: Findings From the CureGN Study. Kidney International Reports, 2018, 3, 1373-1384.	0.8	39
70	Preventing Early Renal Loss in Diabetes (PERL) Study: A Randomized Double-Blinded Trial of Allopurinolâ€"Rationale, Design, and Baseline Data. Diabetes Care, 2019, 42, 1454-1463.	8.6	39
71	Glomerular cell death and inflammation with high-protein diet and diabetes. Nephrology Dialysis Transplantation, 2013, 28, 1711-1720.	0.7	38
72	Health-related quality of life in glomerular disease. Kidney International, 2019, 95, 1209-1224.	5.2	38

#	Article	IF	Citations
73	Much Ado About Nothing, or Much to Do About Something? The Continuing Controversy Over the Role of Uric Acid in Cardiovascular Disease. Hypertension, 2000, 35, E10.	2.7	37
74	Post-acute COVID-19 syndrome and kidney diseases: what do we know?. Journal of Nephrology, 2022, 35, 795-805.	2.0	37
75	Effect of insulin therapy on renal hemodynamic response to amino acids and renal hypertrophy in non-insulin-dependent diabetes. Kidney International, 1992, 42, 167-173.	5.2	36
76	Effects of amino acids and glucagon on renal hemodynamics in type 1 diabetes. American Journal of Physiology - Renal Physiology, 2002, 282, F103-F112.	2.7	36
77	Amino acids injure mesangial cells by advanced glycation end products, oxidative stress, and protein kinase C. Kidney International, 2005, 67, 953-968.	5.2	34
78	Protein kinase C-Î² inhibition for diabetic kidney disease. Diabetes Research and Clinical Practice, 2008, 82, S70-S74.	2.8	34
79	Oxidative Stress Mediates Protein Kinase C Activation and Advanced Glycation End Product Formation in a Mesangial Cell Model of Diabetes and High Protein Diet. American Journal of Nephrology, 2009, 29, 171-180.	3.1	34
80	Prevention of Diabetic Kidney Disease: Negative Clinical Trials With Renin-Angiotensin System Inhibitors. American Journal of Kidney Diseases, 2010, 55, 426-430.	1.9	34
81	Direct and Indirect Effects of Obesity on the Kidney. Advances in Chronic Kidney Disease, 2013, 20, 121-127.	1.4	32
82	Serum Uromodulin: A Biomarker of Long-Term Kidney Allograft Failure. American Journal of Nephrology, 2018, 47, 275-282.	3.1	31
83	GLP-1 receptor agonists in diabetic kidney disease: from the patient-side to the bench-side. American Journal of Physiology - Renal Physiology, 2018, 315, F1519-F1525.	2.7	31
84	Clinical evidence for the influence of uric acid on hypertension, cardiovascular disease, and kidney disease: A statistical modeling perspective. Seminars in Nephrology, 2005, 25, 25-31.	1.6	30
85	We Can Finally Stop Worrying About SGLT2 Inhibitors and Acute Kidney Injury. American Journal of Kidney Diseases, 2020, 76, 454-456.	1.9	30
86	Medication Therapy Management after Hospitalization in CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 231-241.	4.5	29
87	Use of Renin-Angiotensin Inhibitors in People with Renal Artery Stenosis. Clinical Journal of the American Society of Nephrology: CJASN, 2014, 9, 1199-1206.	4.5	28
88	Nephron overload as a therapeutic target to maximize kidney lifespan. Nature Reviews Nephrology, 2022, 18, 171-183.	9.6	28
89	The next generation of diabetic nephropathy therapies: An update. Advances in Chronic Kidney Disease, 2005, 12, 212-222.	1.4	26
90	Effects of Stenting for Atherosclerotic Renal Artery Stenosis on eGFR and Predictors of Clinical Events in the CORAL Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2016, 11, 1180-1188.	4.5	25

#	Article	IF	Citations
91	Cardio-Renal-Metabolic Care Models. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e007264.	2.2	25
92	Renal manifestations of the metabolic syndrome. Nephrology Dialysis Transplantation, 2005, 20, 861-864.	0.7	24
93	Effects of Exenatide on Kidney Function, Adverse Events, and Clinical End Points of Kidney Disease in Type 2 Diabetes. American Journal of Kidney Diseases, 2013, 62, 396-398.	1.9	24
94	Co-occurring mood disorders among hospitalized patients and risk for subsequent medical hospitalization. General Hospital Psychiatry, 2012, 34, 500-505.	2.4	23
95	Serum amyloid a and risk of death and end-stage renal disease in diabetic kidney disease. Journal of Diabetes and Its Complications, 2016, 30, 1467-1472.	2.3	23
96	Sodium Glucose Cotransporter 2 Inhibition Heralds a Call-to-Action for Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 285-288.	4.5	23
97	Observational Study of Kidney Function and Albuminuria in Patients With Type 2 Diabetes Treated With Exenatide BID Versus Insulin Glargine. Annals of Pharmacotherapy, 2014, 48, 571-576.	1.9	22
98	Effect of Ruboxistaurin on Albuminuria and Estimated GFR in People With Diabetic Peripheral Neuropathy: Results From a Randomized Trial. American Journal of Kidney Diseases, 2015, 65, 634-636.	1.9	22
99	Body weight and eGFR during dulaglutide treatment in type 2 diabetes and moderateâ€toâ€severe chronic kidney disease (AWARDâ€7). Diabetes, Obesity and Metabolism, 2019, 21, 1493-1497.	4.4	22
100	Amino acids induce indicators of response to injury in glomerular mesangial cells. American Journal of Physiology - Renal Physiology, 2003, 285, F79-F86.	2.7	21
101	Elevations in serum creatinine with RAAS blockade: why isnÊ¼t it a sign of kidney injury?. Current Opinion in Nephrology and Hypertension, 2008, 17, 443-449.	2.0	21
102	Construct validity, ecological validity and acceptance of self-administered online neuropsychological assessment in adults. Clinical Neuropsychologist, 2021, 35, 148-164.	2.3	21
103	Implications of Chronic Kidney Disease for Dietary Treatment in Cardiovascular Disease. , 2006, 16, 259-268.		20
104	Management of the Diabetic Patient with Advanced Chronic Kidney Disease. Seminars in Dialysis, 2010, 23, 140-147.	1.3	20
105	Integrating Patient Priorities with Science by Community Engagement in the Kidney Precision Medicine Project. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 660-668.	4.5	20
106	Action plan for optimizing the design of clinical trials in chronic kidney disease. Kidney International Supplements, 2017, 7, 138-144.	14.2	19
107	Protein kinase C Î² inhibition: the promise for treatment of diabetic nephropathy. Current Opinion in Nephrology and Hypertension, 2007, 16, 397-402.	2.0	18
108	Novel Therapies for Diabetic Kidney Disease: Storied Past and Forward Paths. Diabetes Spectrum, 2015, 28, 167-174.	1.0	18

#	Article	IF	Citations
109	Safety of Empagliflozin in Patients With Type 2 Diabetes and Chronic Kidney Disease: Pooled Analysis of Placebo-Controlled Clinical Trials. Diabetes Care, 2022, 45, 1445-1452.	8.6	18
110	Atherosclerotic renal artery stenosis: current status and future directions. Current Opinion in Nephrology and Hypertension, 2004, 13, 613-621.	2.0	17
111	Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study. Kidney International Reports, 2020, 5, 1679-1689.	0.8	17
112	Cardiovascular Implications of Albuminuria. Journal of Clinical Hypertension, 2004, 6, 13-17.	2.0	16
113	Ischemic nephropathy. Current Opinion in Nephrology and Hypertension, 2001, 10, 167-173.	2.0	15
114	Safety and Efficacy of GFB-887, a TRPC5 Channel Inhibitor, in Patients With Focal Segmental Glomerulosclerosis, Treatment-Resistant Minimal Change Disease, or Diabetic Nephropathy: TRACTION-2 Trial Design. Kidney International Reports, 2021, 6, 2575-2584.	0.8	15
115	Prevalence of SGLT2i and GLP1RA use among US adults with type 2 diabetes. Journal of Diabetes and Its Complications, 2022, 36, 108204.	2.3	15
116	Renal parenchymal injury as a determinant of clinical consequences in atherosclerotic renal artery stenosis. American Journal of Kidney Diseases, 2002, 39, 1321-1322.	1.9	14
117	Effects of amino acids and glucose on mesangial cell aminopeptidase a and angiotensin receptors. Kidney International, 2002, 61, S106-S109.	5.2	14
118	Association of Co-Occurring Serious Mental Illness with Emergency Hospitalization in People with Chronic Kidney Disease. American Journal of Nephrology, 2014, 39, 260-267.	3.1	14
119	Serum amyloid A and Janus kinase 2 in a mouse model of diabetic kidney disease. PLoS ONE, 2019, 14, e0211555.	2.5	14
120	Clinician engagement in research as a path toward the learning health system: A regional survey across the northwestern United States. Health Services Management Research, 2020, 33, 33-42.	1.7	14
121	The longitudinal relationship between patient-reported outcomes and clinical characteristics among patients with focal segmental glomerulosclerosis in the Nephrotic Syndrome Study Network. CKJ: Clinical Kidney Journal, 2020, 13, 597-606.	2.9	14
122	Clinical Outcomes by Albuminuria Status with Dulaglutide versus Insulin Glargine in Participants with Diabetes and CKD: AWARD-7 Exploratory Analysis. Kidney360, 2021, 2, 254-262.	2.1	14
123	Endovascular stents for renal artery revascularization. Current Opinion in Nephrology and Hypertension, 1998, 7, 695-702.	2.0	13
124	Can Comprehensive Lifestyle Change Alter the Course of Chronic Kidney Disease?. Seminars in Nephrology, 2009, 29, 512-523.	1.6	13
125	Modulation of Advanced Glycation End Products by Candesartan in Patients with Diabetic Kidney Disease-A Dose-Response Relationship Study. American Journal of Therapeutics, 2010, 17, 553-558.	0.9	13
126	Type 2 Translational Research for CKD. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 1829-1838.	4.5	13

#	Article	IF	Citations
127	Urinary excretion of RAS, BMP, and WNT pathway components in diabetic kidney disease. Physiological Reports, 2014, 2, e12010.	1.7	13
128	Association Between Prescription Opioid Use and Biomarkers of Kidney Disease in US Adults. Kidney and Blood Pressure Research, 2016, 41, 365-373.	2.0	13
129	Disseminated Adenovirus Nephritis After Kidney Transplantation. Kidney International Reports, 2018, 3, 19-23.	0.8	13
130	Rationale and design of a multicenter Chronic Kidney Disease (CKD) and at-risk for CKD electronic health records-based registry: CURE-CKD. BMC Nephrology, 2019, 20, 416.	1.8	12
131	Degludec hospital trial: A randomized controlled trial comparing insulin degludec <scp>U100</scp> and glargine <scp>U100</scp> for the inpatient management of patients with type 2 diabetes. Diabetes, Obesity and Metabolism, 2022, 24, 42-49.	4.4	12
132	On the importance of the interplay of residual renal function with clinical outcomes in end-stage kidney disease. Journal of Nephrology, 2022, 35, 2191-2204.	2.0	12
133	Toward more rational management of ischemic nephropathy: The need for clinical evidence. American Journal of Kidney Diseases, 2000, 36, 863-865.	1.9	11
134	Connecting Patients to Prescription Assistance Programs: Effects on Emergency Department and Hospital Utilization. Journal of Managed Care & Specialty Pharmacy, 2016, 22, 381-387.	0.9	11
135	Association of Serum Amyloid A with Kidney Outcomes and All-Cause Mortality in American Indians with Type 2 Diabetes. American Journal of Nephrology, 2017, 46, 276-284.	3.1	11
136	Cigarette smoking and cardio-renal events in patients with atherosclerotic renal artery stenosis. PLoS ONE, 2017, 12, e0173562.	2.5	11
137	Early Rapid Decline in Kidney Function in Medically Managed Patients With Atherosclerotic Renal Artery Stenosis. Journal of the American Heart Association, 2019, 8, e012366.	3.7	11
138	GLP-1 Receptor Agonists in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1578-1580.	4.5	11
139	Transforming the Care of Patients with Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2021, 16, 1590-1600.	4.5	11
140	Integrated single-cell sequencing and histopathological analyses reveal diverse injury and repair responses in a participant with acute kidney injury: a clinical-molecular-pathologic correlation. Kidney International, 2022, 101, 1116-1125.	5.2	11
141	Medication Intervention for Chronic Kidney Disease Patients Transitioning from Hospital to Home: Study Design and Baseline Characteristics. American Journal of Nephrology, 2016, 44, 122-129.	3.1	10
142	Urinary Epidermal Growth Factor as a Marker of Disease Progression in Children With Nephrotic Syndrome. Kidney International Reports, 2020, 5, 414-425.	0.8	10
143	Breaking New Ground with Incretin Therapy in Diabetes. New England Journal of Medicine, 2021, 385, 560-561.	27.0	10
144	Effects of diet and exercise on adipocytokine levels in patients with moderate to severe chronic kidney disease. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1375-1381.	2.6	10

#	Article	IF	Citations
145	Preserving Self: Medicationâ€Taking Practices and Preferences of Older Adults With Multiple Chronic Medical Conditions. Journal of Nursing Scholarship, 2016, 48, 533-542.	2.4	9
146	Overcoming Barriers to Implementing New Therapies for Diabetic Kidney Disease: Lessons Learned. Advances in Chronic Kidney Disease, 2021, 28, 318-327.	1.4	9
147	Do agents that block the RAS truly offer renoprotective effects in early stage, nonproteinuric nephropathy?. Current Hypertension Reports, 2007, 9, 393-402.	3.5	8
148	Dietary strategies for cardiovascular health. Trends in Cardiovascular Medicine, 2017, 27, 295-313.	4.9	8
149	The landscape of diabetic kidney disease transformed. Nature Reviews Nephrology, 2020, 16, 67-68.	9.6	8
150	Association of Obesity with Cardiovascular Risk Factors and Kidney Disease Outcomes in Primary Proteinuric Glomerulopathies. Nephron, 2021, 145, 245-255.	1.8	8
151	Supervised Exercise Intervention and Overall Activity in CKD. Kidney International Reports, 2020, 5, 1261-1270.	0.8	7
152	Clinical Evidence and Proposed Mechanisms for Cardiovascular and Kidney Benefits from Glucagon-like Peptide-1 Receptor Agonists. US Endocrinology, 2020, 16, 80.	0.3	7
153	Influence of Glycemic Control on the Development of Diabetic Cardiovascular and Kidney Disease. Cardiology Clinics, 2010, 28, 497-516.	2.2	6
154	Association of Acute Kidney Injury with Cardiovascular Events and Death in Systolic Blood Pressure Intervention Trial. American Journal of Nephrology, 2019, 49, 359-367.	3.1	6
155	Racial-Ethnic Differences in Health-Related Quality of Life among Adults and Children with Glomerular Disease. Glomerular Diseases, 2021, 1, 105-117.	1.0	6
156	Novel approaches to hypoglycemia and burnt-out diabetes in chronic kidney disease. Current Opinion in Nephrology and Hypertension, 2022, 31, 72-81.	2.0	6
157	Effects of caloric restriction and aerobic exercise on circulating cell-free mitochondrial DNA in patients with moderate-to-severe chronic kidney disease. American Journal of Physiology - Renal Physiology, 2021, , .	2.7	6
158	Prediction of cardiovascular outcomes with machine learning techniques: application to the Cardiovascular Outcomes in Renal Atherosclerotic Lesions (CORAL) study . International Journal of Nephrology and Renovascular Disease, 2019, Volume 12, 49-58.	1.8	5
159	Liraglutide for the Treatment of Type 2 Diabetes and Safety in Diabetic Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2020, 15, 444-446.	4.5	5
160	Evidenceâ€based treatment of hyperglycaemia with incretin therapies in patients with type 2 diabetes and advanced chronic kidney disease. Diabetes, Obesity and Metabolism, 2020, 22, 1014-1023.	4.4	5
161	Patient perspectives and involvement in precision medicine research. Kidney International, 2021, 99, 511-514.	5.2	5
162	Therapeutic transformation for diabetic kidney disease. Kidney International, 2021, 99, 301-303.	5.2	5

#	Article	IF	Citations
163	Optimizing use of SGLT2 inhibitors and other evidence-based therapies to improve outcomes in patients with type 2 diabetes and chronic kidney disease: An opportunity for pharmacists. American Journal of Health-System Pharmacy, 2022, 79, e65-e70.	1.0	5
164	Glycemic Variability and KIM-1â€“Induced Inflammation in the Diabetic Kidney. Diabetes, 2021, 70, 1617-1619.	0.6	5
165	The Northwest Participant and Clinical Interactions Network: Increasing opportunities for patients to participate in research across the Northwestern United States. Journal of Clinical and Translational Science, 2017, 1, 94-100.	0.6	4
166	Premature Death in Kidney Transplant Recipients: The Time for Trials is Now. Journal of the American Society of Nephrology: JASN, 2022, 33, 665-673.	6.1	4
167	The â€œEco-Atkinsâ€•Diet. Archives of Internal Medicine, 2009, 169, 1027.	3.8	3
168	Classification of Chronic Kidney Disease Biomarkers to Predict Coronary Artery Calcium. Kidney and Blood Pressure Research, 2012, 36, 26-35.	2.0	3
169	The Surging Tide of Diabetes: Implications for Nephrology. American Journal of Kidney Diseases, 2016, 67, 364-366.	1.9	3
170	APOL1 genotype-associated morphologic changes among patients with focal segmental glomerulosclerosis. Pediatric Nephrology, 2021, 36, 2747-2757.	1.7	3
171	A Participant-Centered Approach to Understanding Risks and Benefits of Participation in Research Informed by the Kidney Precision Medicine Project. American Journal of Kidney Diseases, 2022, 80, 132-138.	1.9	3
172	More Is Not Always Better: Intensive Glycemic Control in Type 2 Diabetes. American Journal of Kidney Diseases, 2009, 53, 12-15.	1.9	2
173	Charting New Territory by Simulated Modeling of a Clinical Trial. Clinical Journal of the American Society of Nephrology: CJASN, 2010, 5, 750-752.	4.5	2
174	Diabetic Kidney Disease (c. 2018). Advances in Chronic Kidney Disease, 2018, 25, 119-120.	1.4	2
175	A turning point for chronic kidney disease in diabetes. Lancet, The, 2019, 393, 1913-1914.	13.7	2
176	Medication use, reninâ€“angiotensin system inhibitors, and acute care utilization after hospitalization in patients with chronic kidney disease. JRAAS - Journal of the Renin-Angiotensin-Aldosterone System, 2020, 21, 147032032094513.	1.7	2
177	MO051EFFECTS OF SEMAGLUTIDE ON CHRONIC KIDNEY DISEASE OUTCOMES: A POST HOC POOLED ANALYSIS FROM THE SUSTAIN 6 AND PIONEER 6 TRIALS. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
178	TO002REDUCTION IN THE RATE OF EGFR DECLINE WITH SEMAGLUTIDE VS PLACEBO: A POST HOC POOLED ANALYSIS OF SUSTAIN 6 AND PIONEER 6. Nephrology Dialysis Transplantation, 2020, 35, .	0.7	2
179	Persistent Disease Activity in Patients With Long-Standing Glomerular Disease. Kidney International Reports, 2020, 5, 860-871.	0.8	2
180	SGLT2 inhibition and chronic kidney disease outcomes: in diabetes and beyond. Lancet Diabetes and Endocrinology,the, 2021, 9, 3-5.	11.4	2

#	Article	IF	Citations
181	Changing the Trajectory of Heart Failure and Kidney Disease. Clinical Journal of the American Society of Nephrology: CJASN, 2022, , CJN.00470122.	4.5	2
182	Learnings from Throwing Paint at the Wall for COVID-19 with an SGLT2 Inhibitor. Clinical Journal of the American Society of Nephrology: CJASN, 2022, 17, 628-630.	4.5	2
183	Could renin inhibition be the next step forward in the treatment of diabetic kidney disease?. Nature Clinical Practice Endocrinology and Metabolism, 2009, 5, 20-21.	2.8	1
184	Should albuminuria be a focus of antihypertensive therapy goals?. Current Hypertension Reports, 2009, 11, 354-362.	3.5	1
185	Complications and Management of Chronic Kidney Disease. , 2010, , 145-163.		1
186	Diabetic Kidney Disease: A Call to Action: Preface. Diabetes Spectrum, 2015, 28, 158-160.	1.0	1
187	Diabetic Kidney Disease. , 2019, , 42-61.e5.		1
188	Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial. Lancet Diabetes and Endocrinology,the, 2021, 9, 727-728.	11.4	1
189	Diabetic Kidney Disease. Nephrology Self-assessment Program: NephSAP, 2020, 19, 110-139.	3.0	1
190	The authors reply:. Kidney International, 2022, 101, 420-421.	5.2	1
191	GLP-1 receptor agonists, CKD, and eGFR trajectory â€“ Authors' reply. Lancet Diabetes and Endocrinology,the, 2018, 6, 765.	11.4	0
192	Race in America. Clinical Journal of the American Society of Nephrology: CJASN, 2018, 13, 829-830.	4.5	0
193	SGLT2 inhibitor and incretin mimetic therapy for type 2 diabetes and chronic kidney disease. Lancet Diabetes and Endocrinology,the, 2019, 7, 414-415.	11.4	0
194	Feasibility of connecting regional research programs to national multisite trials emanating from the CTSA Trial Innovation Network. Journal of Clinical and Translational Science, 2020, 4, 75-80.	0.6	0
195	The Authors Reply. Kidney International Reports, 2020, 5, 2405-2406.	0.8	0
196	Dietary Paradoxes to Optimize Cardiovascular Risk Management in Chronic Kidney Disease. , 2012, , 213-237.		0
197	Annals On Call - SGLT2 Inhibitors: The Good, the Bad, and the Ugly. Annals of Internal Medicine, 2019, 171, OC1.	3.9	0
198	Inflammatory Mechanisms in Diabetic Kidney Disease. , 2020, , 437-455.		0

#	Article	IF	Citations
199	Annals On Call - The Good, the Bad, and the Uglyâ€”the Sequel: GLP1 Agonists. Annals of Internal Medicine, 2020, 172, OC1.	3.9	0
200	Major Risks Indicators for Diabetic Kidney Disease. , 2006, , 351-357.		0
201	Autopopulus: A Novel Framework for Autoencoder Imputation on Large Clinical Datasets. , 2021, 2021, 2303-2309.		0
202	A perspective on nonsteroidal mineralocorticoid receptor antagonism in diabetic kidney disease. Kidney360, 0, , 10.34067/KID.0007072021.	2.1	0
203	MO198: Outcomes with Finerenone in Patients with Stage 4 Chronic Kidney Disease and Type 2 Diabetes: A Fidelity Subgroup Analysis. Nephrology Dialysis Transplantation, 2022, 37, .	0.7	0